Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05132517
Other study ID # MaSeKo
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 26, 2022
Est. completion date June 30, 2024

Study information

Verified date November 2022
Source BDH-Klinik Hessisch Oldendorf
Contact Simone B Schmidt, Dr.
Phone 0049 5152 781 215
Email si.schmidt@nkho.de
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Cognitive impairments such as memory impairments, word-finding difficulties, compromised orientation and perception are often observed in stroke patients. Low serum-mg-concentrations are associated with cognitive impairments in ischemic stroke patients one month after stroke onset. It is not clear, if cognitive impairments after stroke is caused by the mg-deficiency or by the stroke itself. Until now, no studies investigating the relationship between mg-concentration, stroke severity and cognition during treatment course are available. Thus, this study aimed to investigate the relationship between mg-concentration and cognition of stroke patients.


Description:

Stroke patients admitted to the stroke unit will be included. Initial mg-concentration in serum as well as stroke related measures (National Institutes of Health Stroke Scale, Scandinavian Stroke Scale, modified Rankin Scale) will be ealuated. Moreover, the cognitive abilities of the patient will be assessed within the first three days via the Kölner Neuropsychologische Screening for stroke patients as well as the Mini Mental Status Test. During stroke rehabilitation mg-level, stroke related measures (NIHSS,SSS,MRS) as well as the cognitive tests (MMST,KöpSS) will be re-assed after 4 weeks, 3 month as well as at study end, which is defined as discharge from the clinic (death, transfer to another hospital without return after 4 weeks, discharge to long-term nursing/ home/hospice). Attention-network of stroke patients are measeared if the patient undergo a MRi scan. In this study following questions will be assessed: 1. What is the incidence of cognitive impairments in stroke patients? 1. Are there differences between ischemic and hemorrhagic stroke patients? 2. Are there age and/or gender differences? 2. Are there differences regarding the mg-concentration at admission in comparison to the follow-up (week 4 after admission, 3 month after admission) and between patients with/without cognitive impairments? 3. Is there a correlation between the mg-concentration and the stroke severity? 4. Is there a correlation between the scores of the different cognitive tests (MMST and KöpSS)? 5. Is there an association between the stroke severity, the cognitive impairments (KöpSS) and the neuronal attention network?


Recruitment information / eligibility

Status Recruiting
Enrollment 80
Est. completion date June 30, 2024
Est. primary completion date December 31, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - ischemic/hemmorhagic stroke - written consent form Exclusion Criteria: - pre-existing dementia or cognitive impairment before stroke onset - pre-existing mental disorder (depression) or present/prior long-term treatment (> 6 months) with psychotropic drugs - pre-existing malign tumor disease - participation in another clinical trial within the past 30 days - pregnancy or breastfeeding

Study Design


Intervention

Diagnostic Test:
Kölner Neuropsychologische Screening für Schlaganfall-Patienten
The cognitive state of the patient is measure by the Kölner Neuropsychologische Screening (KöpSS) and by the Mini Mental Status Test (MMST). The MMST is a popular often used test, which makes comparisons to other international studies possible. However, even though this test was specifically designed for stroke patients, it has a limited sensibility. Thus the KöpSS is being used as an additional test demonstrating satisfactory sensibility and specificity. It is suitable for acute and subacute strokes and covers all stroke relevant domains.

Locations

Country Name City State
Germany Institute for Neurorehabilitation Research, BDH-Clinic Hessich Oldendorf Hessisch Oldendorf Lower Saxony

Sponsors (1)

Lead Sponsor Collaborator
BDH-Klinik Hessisch Oldendorf

Country where clinical trial is conducted

Germany, 

References & Publications (3)

Classen und Nowitzki. Serum-Magnesium: Normalwerte und Referenzbereiche. Magnesium-Bulletin 1990; 12(4):127-132.

Kaesberg S, Fink GR, Kalbe E. [Neuropsychological assessment early after stroke--an overview of diagnostic instruments available in German and introduction of a new screening tool]. Fortschr Neurol Psychiatr. 2013 Sep;81(9):482-92. doi: 10.1055/s-0033-135 — View Citation

Tu X, Qiu H, Lin S, He W, Huang G, Zhang X, Wu Y, He J. Low levels of serum magnesium are associated with poststroke cognitive impairment in ischemic stroke patients. Neuropsychiatr Dis Treat. 2018 Nov 2;14:2947-2954. doi: 10.2147/NDT.S181948. eCollection — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other Demographics age, gender, ethnic origin day 1
Other Location and size of insult evaluation by CCT or MRT (if available) day 1
Other Charlson Comorbidity Index (CII) Charlson Comorbidity Index (CII) ranges from 0 to 42, which a score >5 points indicating a 85% mortality risk of one-year death. day 1
Other Secondary diagnoses All secondary diagnoses (i.e. renal insufficiency, Diabetes mellitus, acidosis, alcohol use) which affects mg-absorption and/or -excretion are documented. day 1
Other Medication Medication affecting mg-absorption and/or -excretion is documented. day 1
Primary Serum mg-concentration This study defines a reference value ranging from 1,8 to 2,53 mg/dl. day 1
Primary Change from Serum mg-concentration from admission at day 28 This study defines a reference value ranging from 1,8 to 2,53 mg/dl. day 28
Primary Change from Serum mg-concentration from admission at day 72 This study defines a reference value ranging from 1,8 to 2,53 mg/dl. day 72
Primary Change from Serum mg-concentration from admission at study end This study defines a reference value ranging from 1,8 to 2,53 mg/dl. up to 6 month
Primary Kölner Neuropsychologische Screening für Schlaganfall-Patienten (KöpSS) The score ranges from 0 to 108 points. If all subtest can be performed, a score <98 points identify an impaired cognition. day 3
Primary Change from Kölner Neuropsychologische Screening für Schlaganfall-Patienten (KöpSS) at day 28 The score ranges from 0 to 108 points. If all subtest can be performed, a score <98 points identify an impaired cognition. day 28
Primary Change from Kölner Neuropsychologische Screening für Schlaganfall-Patienten (KöpSS) at day 72 The score ranges from 0 to 108 points. If all subtest can be performed, a score <98 points identify an impaired cognition. day 72
Primary Change from Kölner Neuropsychologische Screening für Schlaganfall-Patienten (KöpSS) at study end The score ranges from 0 to 108 points. If all subtest can be performed, a score <98 points identify an impaired cognition. up to 6 month
Primary National Institutes of Health Stroke Scale 0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke;
=25 points: very severe stroke
day 1
Primary Change from National Institutes of Health Stroke Scale at day 3 0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke;
=25 points: very severe stroke
day 3
Primary Change from National Institutes of Health Stroke Scale at day 28 0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke;
=25 points: very severe stroke
day 28
Primary Change from National Institutes of Health Stroke Scale at day 72 0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke;
=25 points: very severe stroke
day 72
Primary Change from National Institutes of Health Stroke Scale at study end 0-5 points: mild stroke; 6-14 points: moderate stroke; 15- 24 points: severe stroke;
=25 points: very severe stroke
up to 6 month
Primary Lenght of stay Lenght of stay will be assesse at discharge. up to 6 month
Secondary Mini Mental State Test (MMST) 30 - 28 points no dementia; 27 - 25 points mild cognitive decline; 24 - 18 points mild dementia; 17 - 10 points moderate dementia; < 10 points severe dementia day 3
Secondary Change from Mini Mental State Test (MMST) at day 28 30 - 28 points no dementia; 27 - 25 points mild cognitive decline; 24 - 18 points mild dementia; 17 - 10 points moderate dementia; < 10 points severe dementia day 28
Secondary Change from Mini Mental State Test (MMST) at day 72 30 - 28 points no dementia; 27 - 25 points mild cognitive decline; 24 - 18 points mild dementia; 17 - 10 points moderate dementia; < 10 points severe dementia day 72
Secondary Change from Mini Mental State Test (MMST) at study end 30 - 28 points no dementia; 27 - 25 points mild cognitive decline; 24 - 18 points mild dementia; 17 - 10 points moderate dementia; < 10 points severe dementia up to 6 month
Secondary Modified Rankin Scale (MRS) 0 - No symptoms;
1 - No significant disability. Able to carry out all usual activities, despite some symptoms; 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 - Moderate disability. Requires some help, but able to walk unassisted; 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 - Dead.
day 1
Secondary Change from Modified Rankin Scale (MRS) at day 3 0 - No symptoms;
1 - No significant disability. Able to carry out all usual activities, despite some symptoms; 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 - Moderate disability. Requires some help, but able to walk unassisted; 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 - Dead.
day 3
Secondary Change from Modified Rankin Scale (MRS) at day 28 0 - No symptoms;
1 - No significant disability. Able to carry out all usual activities, despite some symptoms; 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 - Moderate disability. Requires some help, but able to walk unassisted; 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 - Dead.
day 28
Secondary Change from Modified Rankin Scale (MRS) at day 72 0 - No symptoms;
1 - No significant disability. Able to carry out all usual activities, despite some symptoms; 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 - Moderate disability. Requires some help, but able to walk unassisted; 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 - Dead.
day 72
Secondary Change from Modified Rankin Scale (MRS) at study end 0 - No symptoms;
1 - No significant disability. Able to carry out all usual activities, despite some symptoms; 2 - Slight disability. Able to look after own affairs without assistance, but unable to carry out all previous activities; 3 - Moderate disability. Requires some help, but able to walk unassisted; 4 - Moderately severe disability. Unable to attend to own bodily needs without assistance, and unable to walk unassisted; 5 - Severe disability. Requires constant nursing care and attention, bedridden, incontinent; 6 - Dead.
up to 6 month
Secondary Scandinavian Stroke Scale (SSS) Sum score range from 0 to 58 in the edited version,with 0 indicating severe neurological deficits and 58 indicating no neurological deficits. day 1
Secondary Change from Scandinavian Stroke Scale (SSS) at day 3 Sum score range from 0 to 58 in the edited version,with 0 indicating severe neurological deficits and 58 indicating no neurological deficits. day 3
Secondary Change from Scandinavian Stroke Scale (SSS) at day 28 Sum score range from 0 to 58 in the edited version,with 0 indicating severe neurological deficits and 58 indicating no neurological deficits. day 28
Secondary Change from Scandinavian Stroke Scale (SSS) at day 72 Sum score range from 0 to 58 in the edited version,with 0 indicating severe neurological deficits and 58 indicating no neurological deficits. day 72
Secondary Change from Scandinavian Stroke Scale (SSS) at study end Sum score range from 0 to 58 in the edited version,with 0 indicating severe neurological deficits and 58 indicating no neurological deficits. up to 6 month
Secondary Early Rehabilitation Barthel Index (ERBI) Sum score range from -325 to 100 points,with 100 indicating independence in the activity of daily living. day 1
Secondary Change from Early Rehabilitation Barthel Index (ERBI) at day 3 Sum score range from -325 to 100 points,with 100 indicating independence in the activity of daily living. day 3
Secondary Change from Early Rehabilitation Barthel Index (ERBI) at day 28 Sum score range from -325 to 100 points,with 100 indicating independence in the activity of daily living. day 28
Secondary Change from Early Rehabilitation Barthel Index (ERBI) at day 72 Sum score range from -325 to 100 points,with 100 indicating independence in the activity of daily living. day 72
Secondary Change from Early Rehabilitation Barthel Index (ERBI) at study end Sum score range from -325 to 100 points,with 100 indicating independence in the activity of daily living. up to 6 month
Secondary International Classification of Functioning Disability and Health (ICF) Assessment A core set consisting of 20 ICF items is used. The severity of each item is scored with zero ("no impairment") to four ("complete impairment"). day 1
Secondary Change from International Classification of Functioning Disability and Health (ICF) Assessment at day 28 A core set consisting of 20 ICF items is used. The severity of each item is scored with zero ("no impairment") to four ("complete impairment"). day 28
Secondary Change from International Classification of Functioning Disability and Health (ICF) Assessment at day 72 A core set consisting of 20 ICF items is used. The severity of each item is scored with zero ("no impairment") to four ("complete impairment"). day 72
Secondary Change from International Classification of Functioning Disability and Health (ICF) Assessment at study end A core set consisting of 20 ICF items is used. The severity of each item is scored with zero ("no impairment") to four ("complete impairment"). up to 6 month
Secondary Early Functional Abilities (EFA) Sum score range from 20 to 100 points,with 100 indicating no impairement. day 1
Secondary Change from Early Functional Abilities (EFA) at day 28 Sum score range from 20 to 100 points,with 100 indicating no impairement. day 28
Secondary Change from Early Functional Abilities (EFA) at day 72 Sum score range from 20 to 100 points,with 100 indicating no impairement. day 72
Secondary Change from Early Functional Abilities (EFA) at study end Sum score range from 20 to 100 points,with 100 indicating no impairement. up to 6 month
Secondary Adverse events and complications All adverse events and complications will be documened. up to 6 month
See also
  Status Clinical Trial Phase
Recruiting NCT04043052 - Mobile Technologies and Post-stroke Depression N/A
Recruiting NCT03869138 - Alternative Therapies for Improving Physical Function in Individuals With Stroke N/A
Completed NCT04034069 - Effects of Priming Intermittent Theta Burst Stimulation on Upper Limb Motor Recovery After Stroke: A Randomized Controlled Trial N/A
Completed NCT04101695 - Hemodynamic Response of Anodal Transcranial Direct Current Stimulation Over the Cerebellar Hemisphere in Healthy Subjects N/A
Terminated NCT03052712 - Validation and Standardization of a Battery Evaluation of the Socio-emotional Functions in Various Neurological Pathologies N/A
Completed NCT00391378 - Cerebral Lesions and Outcome After Cardiac Surgery (CLOCS) N/A
Recruiting NCT06204744 - Home-based Arm and Hand Exercise Program for Stroke: A Multisite Trial N/A
Active, not recruiting NCT06043167 - Clinimetric Application of FOUR Scale as in Treatment and Rehabilitation of Patients With Acute Cerebral Injury
Active, not recruiting NCT04535479 - Dry Needling for Spasticity in Stroke N/A
Completed NCT03985761 - Utilizing Gaming Mechanics to Optimize Telerehabilitation Adherence in Persons With Stroke N/A
Recruiting NCT00859885 - International PFO Consortium N/A
Recruiting NCT06034119 - Effects of Voluntary Adjustments During Walking in Participants Post-stroke N/A
Completed NCT03622411 - Tablet-based Aphasia Therapy in the Chronic Phase N/A
Completed NCT01662960 - Visual Feedback Therapy for Treating Individuals With Hemiparesis Following Stroke N/A
Recruiting NCT05854485 - Robot-Aided Assessment and Rehabilitation of Upper Extremity Function After Stroke N/A
Active, not recruiting NCT05520528 - Impact of Group Participation on Adults With Aphasia N/A
Completed NCT03366129 - Blood-Brain Barrier Disruption in People With White Matter Hyperintensities Who Have Had a Stroke
Completed NCT05805748 - Serious Game Therapy in Neglect Patients N/A
Completed NCT03281590 - Stroke and Cerebrovascular Diseases Registry
Recruiting NCT05993221 - Deconstructing Post Stroke Hemiparesis